Knight Therapeutics Inc. (OTCMKTS:KHTRF) Given Average Rating of “Buy” by Analysts

Knight Therapeutics Inc. (OTCMKTS:KHTRFGet Rating) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $6.81.

Several analysts recently weighed in on KHTRF shares. Knight Equity reduced their price objective on shares of Knight Therapeutics from C$8.00 to C$7.00 in a research note on Friday, March 25th. Stifel Nicolaus lowered shares of Knight Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from C$7.00 to C$5.30 in a report on Friday, March 25th. Finally, Raymond James dropped their target price on shares of Knight Therapeutics from C$8.50 to C$7.50 in a report on Friday, March 25th.

Shares of OTCMKTS KHTRF remained flat at $$4.20 during midday trading on Tuesday. 78 shares of the company’s stock were exchanged, compared to its average volume of 1,407. Knight Therapeutics has a 12-month low of $3.66 and a 12-month high of $4.64. The company’s 50 day moving average price is $4.23 and its 200-day moving average price is $4.20.

Knight Therapeutics Company Profile (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer.

Featured Articles

Analyst Recommendations for Knight Therapeutics (OTCMKTS:KHTRF)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.